Cargando…

Preponderance of endometrial carcinoma in elderly patients

Elderly patients with endometrial carcinoma (EMC) are considered to have a poor clinical outcome. The present study included 79 patients aged ≥70 years with EMC stage I or II according to the International Federation of Gynecology and Obstetrics classification, and it was conducted to analyse the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogane, Naoki, Hori, Shin-Ichi, Yano, Mitsutake, Katoh, Tomomi, Kamoshida, Shingo, Kato, Hisamori, Kameda, Yoichi, Yasuda, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109667/
https://www.ncbi.nlm.nih.gov/pubmed/30155248
http://dx.doi.org/10.3892/mco.2018.1680
Descripción
Sumario:Elderly patients with endometrial carcinoma (EMC) are considered to have a poor clinical outcome. The present study included 79 patients aged ≥70 years with EMC stage I or II according to the International Federation of Gynecology and Obstetrics classification, and it was conducted to analyse the clinicopathological significance of histological type (I or II), depth of myometrial invasion (<1/2 or ≥1/2), lymphovascular invasion (+ or -) and immunohistochemical profile. The aim of these analyses was to determine whether these factors may adversely affect the patient outcome and the underlying mechanisms. The immunohistochemical markers used were estrogen receptor (ER), Ki-67 and p53. The expression of these markers was evaluated as high (+) or low (−). Accordingly, the patients were divided into groups as follows: 54 cases type I vs. 25 cases type II; 48 cases with myometrial invasion <1/2 vs. 31 cases without myometrial invasion ≥1/2; 63 cases with lymphovascular invasion vs. 16 cases without lymphovascular invasion; 57 cases with ER (+) vs. 22 cases with ER (−); 24 cases with Ki-67 (+) vs. 55 cases with Ki-67 (−); and 29 cases with p53 (+) vs. 50 cases with p53 (−). In conclusion, close attention must be paid to elderly patients with EMC due to the tumor's intrinsic aggressiveness, which may include the ER (−) and p53 (+) pattern as an independent poor prognostic factor.